Cargando…
Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor–Induced Thyroiditis
BACKGROUND/OBJECTIVE: Immune checkpoint inhibitors (CPIs) activate antitumoral immune responses and are used to treat multiple types of primary and metastatic malignancies. Thyroid dysfunction is a known immune-related adverse event of CPI therapy. There are few data on the effect of CPI and CPI-ind...
Autores principales: | Chen, Dennis H., Lenz, Heinz-Josef, Lechner, Melissa G., Angell, Trevor E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Clinical Endocrinology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509378/ https://www.ncbi.nlm.nih.gov/pubmed/37736314 http://dx.doi.org/10.1016/j.aace.2023.05.009 |
Ejemplares similares
-
Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma
por: Angell, Trevor E., et al.
Publicado: (2017) -
Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
por: Pani, Fabiana, et al.
Publicado: (2022) -
Identification of RORg(+)T Cells as Key Players in Thyroid Autoimmunity From Checkpoint Immunotherapy
por: Lechner, Melissa G, et al.
Publicado: (2021) -
Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma
por: Banerjee, Sohini, et al.
Publicado: (2022) -
The indices of body size and aggressiveness of papillary thyroid carcinoma
por: Kim, Ju-Yeon, et al.
Publicado: (2011)